Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.57 |
| ▸ | KDR | P35968 | 13/20 | 0.57 |
| ▸ | PLK4 | O00444 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 3/20 | 0.45 |
| ▸ | IKBKB | O14920 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | LYN | P07948 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | MARK3 | P27448 | 2/20 | 0.44 |
| ▸ | BLK | P51451 | 2/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.44 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136988 | 0.90 | MET (0.57) | METKDRNPC1MAPTMAPK1 | |
| SCHEMBL4730654 | 0.80 | MET (0.70) | METKDRJAK2JAK3 | |
| SCHEMBL14836435 | 0.78 | IKBKB (0.48) | METKDRPLK4AURKAIKBKB | |
| SCHEMBL16617012 | 0.77 | AURKA (0.49) | METKDRPLK4AURKAIKBKB | |
| SCHEMBL4733743 | 0.77 | RAF1 (0.54) | METKDRNPC1RAB9A | |
| SCHEMBL4731957 | 0.77 | GCK (0.46) | METKDRGSK3A | |
| SCHEMBL4730251 | 0.76 | MET (0.44) | METMAP4K4 | |
| SCHEMBL2763172 | 0.75 | MET (0.44) | METKDRGSK3A | |
| SCHEMBL24741603 | 0.73 | MEN1 (0.54) | MAP4K4SYKNPC1RAB9A | |
| SCHEMBL30108336 | 0.73 | MEN1 (0.54) | MAP4K4SYKNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | MET 545/4885KDR 746/4885PLK4 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.